rLIF administration inhibits the elevation of MHC-II expression on IECs and donor T cell activation after allo-BMT. (A-B) Allo-BMT increased MHC-II presentation on IECs, which was reduced by administering rLIF in mice. (A, left) Representative histograms (left) and quantifications of mean florescence intensity (MFI) (right) of MHC-II levels on IECs from B6C3F1 mice at 7 days after allo-BMT. (A, right) Representative histograms (left) and quantifications of MFI (right) of MHC-II levels on IECs from C57BL/6 mice at 10 days after allo-BMT. For B6C3F1 recipients, n = 3 for BM; n = 8 for both BM + T and BM + T + rLIF; for C57BL/6 recipients, n = 3 for BM; n = 10 for both BM + T and BM + T + rLIF. (B, upper) Representative immunofluorescence staining of MHC-II levels on IECs in the SI from C57BL/6 mice at different days after allo-BMT. (B, lower) Quantifications of MHC-II MFI. n ≥ 3 mice/group. (C) The number of donor activated T cells in the MLN (upper) and LP (lower) tissues from B6C3F1 mice at 7 days after allo-BMT with or without rLIF administration. n ≥ 8 mice/group. Data are presented as mean ± standard deviation. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, unpaired t test with Welch’s correction.